L3VLUP
ProSign in

RGEN · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RGENAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RGEN
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterRGENAMGN
Q3 202011 holders, $1.1bn16 holders, $16.3bn
Q4 202011 holders, $1.6bn19 holders, $14.0bn
Q1 202113 holders, $1.4bn16 holders, $14.5bn
Q2 202113 holders, $1.5bn23 holders, $13.8bn
Q3 202112 holders, $2.0bn24 holders, $11.6bn
Q4 202114 holders, $1.9bn21 holders, $10.4bn
Q1 202210 holders, $1.5bn23 holders, $9.9bn
Q2 20228 holders, $1.8bn28 holders, $9.7bn
Q3 20229 holders, $1.7bn21 holders, $7.9bn
Q4 20229 holders, $1.7bn24 holders, $9.3bn
Q1 20238 holders, $1.6bn22 holders, $8.4bn
Q2 20236 holders, $1.1bn26 holders, $7.4bn
Q3 20237 holders, $1.6bn26 holders, $8.7bn
Q4 20238 holders, $1.6bn24 holders, $8.4bn
Q1 20248 holders, $1.5bn25 holders, $6.7bn
Q2 202410 holders, $959m20 holders, $8.0bn
Q3 202410 holders, $1.3bn21 holders, $8.8bn
Q4 202411 holders, $1.7bn20 holders, $8.2bn
Q1 202511 holders, $1.7bn25 holders, $12.0bn
Q2 202510 holders, $1.5bn20 holders, $10.2bn
Q3 202513 holders, $1.5bn17 holders, $10.4bn
Q4 202512 holders, $2.0bn19 holders, $18.0bn
Q1 20269 holders, $1.2bn15 holders, $21.4bn
Q2 202610 holders, $1.2bn23 holders, $24.9bn
RGEN

Repligen Corp

Holders
11
Reported value
$1.7bn
Buyers
7
Sellers
5

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
25
Reported value
$12.0bn
Buyers
10
Sellers
16

Breadth -6 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RGEN (7)

Artisan Partners LP, Citadel Advisors LLC, ExodusPoint Capital Management LP, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Walleye Capital LLC

Only AMGN (21)

Acadian Asset Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →